热脉动治疗在睑板腺功能障碍和干眼管理中的应用:美国眼科学会报告
该报告由美国眼科学会(AAO)基于2022年6月和2023年3月两次PubMed文献检索,纳入11项研究(8项Ⅰ级证据、3项Ⅱ级证据),评估热脉动技术改善睑板腺功能障碍(MGD)和干眼体征或症状的疗效与安全性。单次12分钟LipiFlow热脉动治疗在1至12个月内可安全改善主观或客观指标,但部分Ⅰ级研究显示与传统热敷或眼睑清洁无显著差异;长期疗效和成本效益尚不确定,结论仅限于LipiFlow系统。
要点
- 单次12分钟LipiFlow热脉动治疗在1至12个月内可安全改善MGD或干眼的主观或客观指标。
- 11项研究中9项报告热脉动优于标准热敷和眼睑清洁,但4项存在相关行业利益冲突。
- 8项Ⅰ级证据中4项有行业支持,2项无直接行业参与的Ⅰ级研究结论为无显著差异。
核心结论
- 根据当前文献,单次热脉动治疗可能安全地改善MGD和干眼的主观或客观参数。
- 8项Ⅰ级研究中有4项存在行业支持和参与。
- 疗效持续超过数月以及成本效益仍不确定。
- 由于本评估的纳入参数仅涵盖LipiFlow系统,结论仅限于该产品。
研究设计与样本
- 美国眼科学会(AAO)组织专家小组,于2022年6月和2023年3月在PubMed数据库进行文献检索,纳入英文发表的关于热脉动治疗MGD或干眼的研究。
- 检索获得59条引文,11篇文章符合所有纳入标准;方法学家对每项研究评定证据等级,8项为Ⅰ级证据,3项为Ⅱ级证据。
- 所有纳入研究均评估单次12分钟使用LipiFlow自动热脉动系统(TearScience, Inc, 或 Johnson & Johnson)的治疗。
主要发现
- 与不治疗相比,热脉动治疗后1至12个月内可检测到MGD或干眼主观和客观指标的改善。
- 大多数研究(9/11)报告热脉动疗效优于标准热敷和眼睑清洁治疗。
- 4项研究显示相关的行业利益冲突。
- 4项无直接行业参与的Ⅰ级研究中有2项结论为热脉动治疗与传统眼睑清洁或热敷对照无显著差异(一项在症状方面,另一项在客观检查结果方面)。
- 11项研究中均未报告严重不良事件。
临床怎么用
- 根据当前文献,单次热脉动治疗可能安全地改善MGD和干眼的主观或客观参数。
- 疗效持续超过数月以及成本效益仍不确定。
- 结论仅限于LipiFlow系统。
- 需要高质量独立研究评估该干预的长期获益。
局限性
- 8项Ⅰ级研究中有4项存在行业支持和参与。
- 疗效持续超过数月以及成本效益仍不确定。
- 由于本评估的纳入参数仅涵盖LipiFlow系统,结论仅限于该产品。
- 需要高质量独立研究评估该干预的长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the literature to determine the efficacy and safety of thermal pulsation technologies in improving signs or symptoms of meibomian gland dysfunction (MGD) and dry eye compared with no therapy or with conventional warm compress therapy or eyelid hygiene. METHODS: A literature search was conducted in the PubMed database in June 2022 and again in March 2023 to identify all studies in the English language on the use of thermal pulsation to treat MGD or dry eye. The search yielded 59 citations, and 11 articles met all of the inclusion criteria. The panel methodologist then assigned a level of evidence rating for each study; 8 studies were rated level I evidence and 3 studies were rated level II evidence. RESULTS: All included studies evaluated a single 12-minute session using the LipiFlow automated thermal pulsation system (TearScience, Inc, or Johnson & Johnson). Improvements were detected in subjective and objective metrics of MGD or dry eye in patients within 1 to 12 months of thermal pulsation treatment compared with nontreatment. Most of the studies (9/11) reported greater efficacy with thermal pulsation than with standard warm compress therapy and eyelid hygiene. Four of these studies showed relevant industry conflicts of interest. Two of the 4 level I studies without direct industry participation concluded that thermal pulsation treatment was not significantly different from conventional hygiene or warm compress therapy control treatments (in symptoms in one of the studies and in objective findings in the second study). No serious adverse events were reported in any of the 11 studies. CONCLUSIONS: According to the current literature, a single thermal pulsation session may improve subjective or objective parameters of MGD and dry eye safely. However, industry support and participation were present in 4 of the 8 level I studies. The durability beyond several months and cost efficacy remain uncertain. Because the inclusion parameters of this assessment captured only the LipiFlow system, the conclusions are limited to that product. High-quality independent studies are needed to assess the long-term benefits of this intervention. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Tao JP, Shen JF, Aakalu VK, et al. Thermal Pulsation in the Management of Meibomian Gland Dysfunction and Dry Eye: A Report by the American Academy of Ophthalmology. Ophthalmology. 2023. PMID: 37642619. doi:10.1016/j.ophtha.2023.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。